Sentences with phrase «effector functions of»

The adenosine A ₂ ₐ receptor is the main adenosine receptor expressed on immune cell subsets including T - cells, NK cells and dendritic cells and binding of adenosine to the A ₂ ₐ receptor on immune cells blocks the activation and effector functions of anti-tumor immune cells and promotes a regulatory, immune - suppressive phenotype.

IFN - γ production is one of the primary effector functions of activated CD8 T cells in response to LCMV infection, and has been shown to be a key component of mortality in the naive mouse model of FHL2 (8).

Binding of adenosine to the A2A receptor on immune cells blocks the activation and effector functions of anti-tumor immune cells and promotes a regulatory, immune - suppressive phenotype.

These results suggest GSK2636771 treatment can «synergize» with OX40 agonist antibodies to augment effector functions of tumor - reactive T cells.»

Not exact matches

Single - cell differential gene expression analysis revealed a spectrum of known transcripts, including several linked to cytotoxic and costimulatory function that are expressed at higher levels in the TEMRA (effector memory T cells expressing CD45RA) subset, which is highly enriched for CD4 - CTLs, compared with CD4 + T cells in the central memory (TCM) and effector memory (TEM) subsets.

Further insight into the basic details of CRISPR - Cas structure, functions, and biology — and characterization of new Cas effector proteins in particular — is crucial for optimizing and further expanding the diverse applications of CRISPR - Cas systems.

These include examinations of the effect of antigen structure on the spectrum of cytokines produced after either in vivo or in vitro stimulation, as well as the ability to anergize Vα14 iNKT cells in terms of cytokine production and effector function by prior antigen challenge.

We have shown that invariant Natural Killer T cells (iNKT), a subset of CD1d - restricted T cells displaying innate effector functions, rewire the prostate cancer microenvironment leading to cancer control.

Strength of PD - 1 signaling differentially affects T - cell effector functions.

Therefore the group studies with sophisticated imaging technology in vitro and ex vivo: i) the molecular mechanism driving the migration of HIV through the intestinal epithelial barrier; ii) the cellular targets in the mucosa, in specific macrophages and DCs, to identify the possible pathways to invade the tissue and disseminate to other organs; iii) the involvement of DCs and their functional properties in mediating adaptive immune responses at mucosal level; and iv) the role of antibodies with different effector functions in changing the pathways of the virus.

The Pseudomonas syringae type III effector AvrRpt2 functions downstream or independently of SA to promote virulence on Arabidopsis thaliana

This demonstrates that aging is associated with a marked accumulation of CMV - specific CD8 T cells together with a decrease in immediate effector function.

Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels

To reverse the attenuating effects of potassium on T cell effector function, the team genetically engineered tumour - specific T cells to express additional molecular pumps that specifically remove surplus potassium from the cell.